What Tango Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 11 | 30 |
| Total trades | 15 | 53 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 64,000 | 809,382 |
| Disposed | 79,231 | 398,575 |
| Net activity | −15,231 | +410,807 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D | Nov 11 | Open-market sale · S | −5,000 | $25.00 | −$125K | 115,743 |
| Crystal Adam | President, R&D | Nov 11 | Exercise / conversion · M | +5,000 | $2.91 | +$14.6K | 120,743 |
| Crystal Adam | President, R&D | Nov 02 | Open-market sale · S | −1,100 | $22.99 | −$25.3K | 115,743 |
| Crystal Adam | President, R&D | Nov 02 | Open-market sale · S | −3,900 | $22.26 | −$86.8K | 116,843 |
| Crystal Adam | President, R&D | Nov 02 | Exercise / conversion · M | +5,000 | $2.91 | +$14.6K | 120,743 |
| Newcomb Jessica | Principal Accounting Officer | Nov 02 | Open-market sale · S | −1,460 | $22.98 | −$33.6K | 52,090 |
| Newcomb Jessica | Principal Accounting Officer | Nov 02 | Open-market sale · S | −5,571 | $22.28 | −$124K | 53,550 |
| Crystal Adam | President, R&D | Oct 01 | Open-market sale · S | −600 | $25.32 | −$15.2K | 115,743 |
| Crystal Adam | President, R&D | Oct 01 | Open-market sale · S | −26,400 | $24.45 | −$646K | 116,343 |
| Crystal Adam | President, R&D | Oct 01 | Exercise / conversion · M | +27,000 | $5.20 | +$140K | 142,743 |
| Newcomb Jessica | Principal Accounting Officer | Sep 22 | Open-market sale · S | −2,400 | $25.17 | −$60.4K | 59,121 |
| Newcomb Jessica | Principal Accounting Officer | Sep 22 | Open-market sale · S | −5,100 | $23.97 | −$122K | 61,521 |
| Newcomb Jessica | Principal Accounting Officer | Sep 22 | Open-market sale · S | −700 | $22.80 | −$16K | 66,621 |
| Crystal Adam | President, R&D | Sep 01 | Open-market sale · S | −27,000 | $22.37 | −$604K | 115,743 |
| Crystal Adam | President, R&D | Sep 01 | Exercise / conversion · M | +27,000 | $5.20 | +$140K | 142,743 |
| Crystal Adam | President, R&D | Aug 03 | Open-market sale · S | −21,733 | $27.35 | −$594K | 115,743 |
| Crystal Adam | President, R&D | Aug 03 | Open-market sale · S | −5,267 | $26.79 | −$141K | 137,476 |
| Crystal Adam | President, R&D | Aug 03 | Exercise / conversion · M | +27,000 | $5.20 | +$140K | 142,743 |
| Crystal Adam | President, R&D | Jul 01 | Open-market sale · S | −7,371 | $30.25 | −$223K | 115,743 |
| Crystal Adam | President, R&D | Jul 01 | Open-market sale · S | −19,629 | $29.34 | −$576K | 123,114 |
Loading...